133 related articles for article (PubMed ID: 7629427)
21. Effects of antiestrogen versus antiprogestin on transformed and nontransformed steroid receptors.
Turner JW; Ruh MF; Ward DT; Ruh TS
J Steroid Biochem Mol Biol; 1991 Feb; 38(2):197-203. PubMed ID: 2004041
[TBL] [Abstract][Full Text] [Related]
22. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation.
Banerjee S; Saxena N; Sengupta K; Tawfik O; Mayo MS; Banerjee SK
Neoplasia; 2003; 5(1):63-73. PubMed ID: 12659671
[TBL] [Abstract][Full Text] [Related]
23. Expression of 67 kDa laminin receptor in human breast cancer cells: regulation by progestins.
Shi YE; Torri J; Yieh L; Sobel ME; Yamada Y; Lippman ME; Dickson RB; Thompson EW
Clin Exp Metastasis; 1993 May; 11(3):251-61. PubMed ID: 8472397
[TBL] [Abstract][Full Text] [Related]
24. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
[TBL] [Abstract][Full Text] [Related]
25. Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells.
Jeng MH; Langan-Fahey SM; Jordan VC
Endocrinology; 1993 Jun; 132(6):2622-30. PubMed ID: 8504763
[TBL] [Abstract][Full Text] [Related]
26. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
27. Estrogenic effects of nonylphenol on pS2, ER and MUC1 gene expression in human breast cancer cells-MCF-7.
Ren L; Marquardt MA; Lech JJ
Chem Biol Interact; 1997 Apr; 104(1):55-64. PubMed ID: 9158695
[TBL] [Abstract][Full Text] [Related]
28. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor.
Meyer ME; Pornon A; Ji JW; Bocquel MT; Chambon P; Gronemeyer H
EMBO J; 1990 Dec; 9(12):3923-32. PubMed ID: 2249658
[TBL] [Abstract][Full Text] [Related]
29. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.
McFall T; Patki M; Rosati R; Ratnam M
Oncotarget; 2015 Oct; 6(32):33146-64. PubMed ID: 26356672
[TBL] [Abstract][Full Text] [Related]
30. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
31. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture.
Vignon F; Bardon S; Chalbos D; Rochefort H
J Clin Endocrinol Metab; 1983 Jun; 56(6):1124-30. PubMed ID: 6682424
[TBL] [Abstract][Full Text] [Related]
32. Antiprogestin-receptor complexes: differences in the interaction of the antiprogestin RU38,486 and the progestin R5020 with the progesterone receptor of human breast cancer cells.
Mullick A; Katzenellenbogen BS
Biochem Biophys Res Commun; 1986 Feb; 135(1):90-7. PubMed ID: 3954780
[TBL] [Abstract][Full Text] [Related]
33. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies.
Elashry-Stowers D; Zava DT; Speers WC; Edwards DP
Cancer Res; 1988 Nov; 48(22):6462-74. PubMed ID: 3180062
[TBL] [Abstract][Full Text] [Related]
34. Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells.
Dauvois S; Simard J; Dumont M; Haagensen DE; Labrie F
Mol Cell Endocrinol; 1990 Oct; 73(2-3):171-8. PubMed ID: 2269395
[TBL] [Abstract][Full Text] [Related]
35. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines.
Schoonen WG; Joosten JW; Kloosterboer HJ
J Steroid Biochem Mol Biol; 1995 Dec; 55(3-4):439-44. PubMed ID: 8541241
[TBL] [Abstract][Full Text] [Related]
36. Characterization and regulation of estrogen and progesterone receptors in breast cancer.
Read LD; Katzenellenbogen BS
Cancer Treat Res; 1992; 61():277-99. PubMed ID: 1360237
[No Abstract] [Full Text] [Related]
37. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor.
Bardon S; Vignon F; Chalbos D; Rochefort H
J Clin Endocrinol Metab; 1985 Apr; 60(4):692-7. PubMed ID: 3972969
[TBL] [Abstract][Full Text] [Related]
38. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?
Rosenberg Zand RS; Grass L; Magklara A; Jenkins DJ; Diamandis EP
Breast Cancer Res Treat; 2000 Mar; 60(1):1-8. PubMed ID: 10845803
[TBL] [Abstract][Full Text] [Related]
39. Autologous down-regulation of messenger ribonucleic acid and protein levels for estrogen receptors in MCF-7 cells: an inverse correlation to progesterone receptor levels.
Ree AH; Landmark BF; Eskild W; Levy FO; Lahooti H; Jahnsen T; Aakvaag A; Hansson V
Endocrinology; 1989 May; 124(5):2577-83. PubMed ID: 2651098
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
Davaadelger B; Murphy AR; Clare SE; Lee O; Khan SA; Kim JJ
Endocrinology; 2018 Oct; 159(10):3581-3595. PubMed ID: 30203004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
